Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...
An FTC official told reporters the $7.3 billion figure could be an underestimation. PBM-affiliated pharmacy dispensing revenue increased at an annual growth rate of 42% from 2017 to 2021 ...
A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback